Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IGNX001 in peanut allergy
NCT06331728Phase 1Completed
- Sponsor
- IgGenix
- Start
- Sep 2024
- Primary completion
- Nov 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in peanut allergy comparing IGNX001 with Placebo (2 arms). Primary endpoints: Treatment Emergent Adverse Events at 13 weeks, Serious Adverse Events at 13 weeks and 4 more. Started Sep 2024; status: completed.
02
Drugs
IGNX001
03
Conditions
peanut allergy
Beyond the preview
Go deeper on NCT06331728.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06331728.